Peptide Mapping of a Monoclonal Antibody Using Poroshell 120
Protein-based pharmaceutical drugs, such as fusion proteins and monoclonal antibodies (mAb), are playing an increasing role in modern therapeutics.
Susanne C. Moyer, Agilent Technologies, Inc.
Protein-based pharmaceutical drugs, such as fusion proteins and monoclonal antibodies (mAb), are playing an increasing role in modern therapeutics. Analytical characterization of protein therapeutics is very complex and time consuming. One type of analysis that is undertaken to determine the primary structure of the protein is peptide mapping. In peptide mapping analysis, it is imperative that 100% sequence coverage be achieved and that modifications to the molecule are identified. Typical LC–MS peptide mapping protocols can have LC gradients in excess of 100 min. Obviously, such lengthy run times adversely affect throughput capabilities and methods for reducing these run times while achieving analytical goals are needed. The Agilent Poroshell 120-SB C18 column was used for the LC–MS analysis of a tryptic digest of a monoclonal antibody standard to demonstrate a greatly reduced analysis time of 20 min while achieving 100% sequence coverage of both the heavy and the light chains.
Experimental Conditions
A 3.0 × 150 mm Agilent Poroshell 120 SB-C18 column (PN 683975-302) was used with an Agilent 1200 LC and 6520 QTOF for peptide mapping experiments. Mobile phase A: 0.1% formic acid in water and mobile phase B: 0.1% formic acid in acetonitrile. The flow rate of the column was 0.3 mL/min and the column temperature was maintained at 40 °C. The LC gradient was: 0–3 min 2%B, 3–13 min 2%–45%B, 13–15 min 45%–65%B, 15–15.1 min 65%–90%B, 15.1–17 min 90%B, 17–18 min 90%–2%B, stop time 20 min.
Results and Discussion
Complex tryptic digests of mAbs employ shallow gradients, often stepped, to separate the many peptide fragments into discreet peaks. Often tryptic maps take 2 h to complete using 2.1 × 250 mm, 5 μm particle-sized columns, significantly affecting laboratory productivity. Sample degradation also may occur between long injection cycles so any reduction in analysis time is welcome.
One way to achieve shorter analysis times is to use Poroshell 120 columns. These columns contain 2.7 μm superficially porous particles that provide almost equivalent efficiency to UHPLC (sub-two micron totally porous) columns. Thus, more efficient Poroshell 120 particles packed in a shorter column length can provide similar chromatographic results to their longer 5 μm predecessors in a fraction of the time.
A tryptic digestion of a standard 10 pmol mAb was injected five times onto a Poroshell 120 column. Total analysis time including gradient re-equilibration was only 20 min. Figure 1 shows the five overlays of the total ion chromatograms (TIC). Good retention time, reproducibility, and peak-to-peak resolution indicate a stable instrument, column, and mobile phase gradient and re-equilibration, and is the first indicator of a robust method for validation. Also, Poroshell 120 columns have larger frit pores compared to smaller sub-two micron column frits, to resist plugging from "dirty" or complex samples such as protein hydrolysates.
Figure 1: Rapid analysis of an mAb peptide map using a Poroshell 120, 3.0 Ã150 mm (PN683975-302).
The faster analysis gained from Poroshell 120 did not compromise the chromatographic map of the mAb. Figure 2 shows the results from Agilent MassHunter Molecular Feature Extractor (MFE). MFE is an algorithm that uses the LC retention time and the QTOF accurate mass to extract unique compounds from the data set. These MFE compound results are then matched back to the heavy chain and light chain protein sequences from the mAb standard. This 20 min Poroshell-120 method resulted in 100% sequence coverage for both the heavy and light chains of the mAb.
Figure 2: 100% sequence coverage achieved of mAb with many unique compounds identified using MassHunter.
Conclusion
The Poroshell 120 SB-C18 column can greatly reduce the analysis time of an LC–MS peptide mapping experiment, while achieving high-performance and highly reproducible peptide separations. The combination of highly efficient 2.7 μm superficially porous particles and relatively large pored frits make Poroshell 120 ideal for analysis if complex samples such as mAb digests.
References
(1) L.W. Dick Jr. et al., J. Chromatogr. B, 877 230–236, (2009).
Agilent Technologies, Inc.
2850 Centerville Road, Wilmington, DE 19808
tel. (800) 227-9770; fax (302) 633-8901
SEC-MALS of Antibody Therapeutics—A Robust Method for In-Depth Sample Characterization
June 1st 2022Monoclonal antibodies (mAbs) are effective therapeutics for cancers, auto-immune diseases, viral infections, and other diseases. Recent developments in antibody therapeutics aim to add more specific binding regions (bi- and multi-specificity) to increase their effectiveness and/or to downsize the molecule to the specific binding regions (for example, scFv or Fab fragment) to achieve better penetration of the tissue. As the molecule gets more complex, the possible high and low molecular weight (H/LMW) impurities become more complex, too. In order to accurately analyze the various species, more advanced detection than ultraviolet (UV) is required to characterize a mAb sample.
